Baseline characteristics—full analysis set
| Parameter | Cannabis extract (N=143) | Placebo (N=134) |
| Time since first diagnosis of MS | ||
| Mean±SD (years) | 14.5±9.5 | 15.1±8.4 |
| Median (range) (years) | 13.0 (0–40) | 14.0 (2–34) |
| Form of MS | ||
| Relapsing–remitting (n (%)) | 13 (9.1) | 8 (6.0) |
| Primary progressive (n (%)) | 34 (23.8) | 32 (23.9) |
| Secondary progressive (n (%)) | 96 (67.1) | 94 (70.1) |
| Ambulatory status at screening | ||
| Non-walking (n (%)) | 31 (21.7) | 32 (23.9) |
| Walking (n (%)) | 112 (78.3) | 102 (76.1) |
| Baseline status of body pain | ||
| Low* (n (%)) | 49 (34.3) | 54 (40.3) |
| High† (n (%)) | 94 (65.7) | 80 (59.7) |
| Baseline status of muscle spasms | ||
| Low* (n (%)) | 27 (18.9) | 33 (24.6) |
| High† (n (%)) | 116 (81.1) | 101 (75.4) |
| Baseline status of quality of sleep | ||
| Low* (n (%)) | 47 (32.9) | 54 (40.3) |
| High† (n (%)) | 96 (67.1) | 80 (59.7) |
| Use of spasticity medication | ||
| Yes (n (%)) | 85 (59.4) | 85 (63.4) |
| No (n (%)) | 58 (40.6) | 49 (36.6) |
| Use of analgesic medication | ||
| Yes (n (%)) | 83 (58.0) | 76 (56.7) |
| No (n (%)) | 60 (42.0) | 58 (43.3) |
↵* Categories 0–4 in the rating scale of the amount of the respective symptom at baseline.
↵† Categories 5–10 in the rating scale of the amount of the respective symptom at baseline.
%, percentage based on N; MS, multiple sclerosis; n, number of patients in specified category; N, number of patients in specified treatment group.